Is Saturation Biopsy Still a Viable Alternative to Fusion Biopsy in the Era of Multiparametric MRI? A Comparative Analysis in Patients With Prior Negative Biopsy
| dc.contributor.author | Taskiran, Arda Taskin | |
| dc.contributor.author | Senoglu, Yusuf | |
| dc.date.accessioned | 2026-07-01T11:40:15Z | |
| dc.date.available | 2026-07-01T11:40:15Z | |
| dc.date.issued | 2026 | |
| dc.department | Düzce Üniversitesi | |
| dc.description.abstract | Background: We aimed to compare the diagnostic accuracy of transrectal ultrasound (TRUS)-guided saturation biopsy (SB) and multiparametric MRI (mpMRI)-TRUS fusion-guided combined biopsy (CB) in patients with prior negative prostate biopsies. Methods: We retrospectively analyzed data from 160 patients who underwent transrectal prostate biopsy between January 2014 and March 2021. All had at least one prior negative biopsy. 80 patients underwent SB with a 20-core TRUS-guided approach. The remaining 80 patients, with mpMRI-detected PIRADS >= 3 lesions, underwent CB including 12-core systematic plus 2-4 targeted cores per lesion. Prostate cancer and clinically significant prostate cancer (csPCa) detection rates, and clinical parameters were compared between groups. Results: The groups had no statistically significant differences in baseline characteristics. The PCa detection rate was 20% in the CB group and 16.3% in the SB group (p = 0.682). csPCa detection rates were also similar: 11.3% in the CB cohort and 7.5% in the SB cohort (p = 0.589). Notably, the CB subgroup with PI-RADS >= 4 lesions had a significantly higher csPCa detection rate (28.6%) than SB group (7.5%) (p = 0.016). Patients diagnosed with PCa had significantly lower free PSA and free/total PSA ratios (p < 0.05). Complication rates were low and similar in both groups. Conclusions: CB demonstrates the highest diagnostic yield for detecting csPCa, particularly in patients with PI-RADS >= 4 lesions. However, in resource-limited settings lacking mpMRI, systematic saturation biopsy remains a viable, safe, and effective alternative. PSA derivatives may serve as complementary tools to refine biopsy decisions. | |
| dc.identifier.doi | 10.1002/pros.70169 | |
| dc.identifier.endpage | 996 | |
| dc.identifier.issn | 0270-4137 | |
| dc.identifier.issn | 1097-0045 | |
| dc.identifier.issue | 9 | |
| dc.identifier.orcid | 0000-0003-4556-3475 | |
| dc.identifier.pmid | 41911500 | |
| dc.identifier.scopus | 2-s2.0-105034298861 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 990 | |
| dc.identifier.uri | https://doi.org/10.1002/pros.70169 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12684/23721 | |
| dc.identifier.volume | 86 | |
| dc.identifier.wos | WOS:001728622000001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Prostate | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20260623 | |
| dc.subject | [Keyword Not Available] | |
| dc.title | Is Saturation Biopsy Still a Viable Alternative to Fusion Biopsy in the Era of Multiparametric MRI? A Comparative Analysis in Patients With Prior Negative Biopsy | |
| dc.type | Article |












